NAVCO Pharmaceuticals Inc
Share Statistics
As of March 31, 2023, NAVCO Pharmaceuticals Inc has 2.30M shares outstanding.
| Shares Outstanding | 2.30M |
Financial Position
As of March 31, 2023, NAVCO Pharmaceuticals Inc maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | 4.00 |
Financial Efficiency
Over the twelve months ended March 31, 2023, NAVCO Pharmaceuticals Inc posted a negative return on equity (ROE) of -171.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -45.68, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -171.68 |
| Return on Assets (ROA) | -45.68 |
Income Statement
CADOver the twelve months ended March 31, 2023, NAVCO Pharmaceuticals Inc generated - - in revenue and converted that into -46,978.00 in net income, yielding earnings per share of -0.02. EBITDA reached -52,988.00, while operating income came in at -52,988.00.
| Operating Income | -52,988.00 |
| Pretax Income | -46,978.00 |
| Net Income | -46,978.00 |
| EBITDA | -52,988.00 |
| EBIT | -52,988.00 |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
CADAs of March 31, 2023, NAVCO Pharmaceuticals Inc holds - - in cash and equivalents against 155.00 in total debt, resulting in a net debt position of 155.00. Total book value stands at 3,874.00, with working capital of 3,874.00 providing operational flexibility.
| Total Debt | 155.00 |
| Net Debt | 155.00 |
| Equity (Book Value) | 3,874.00 |
| Working Capital | 3,874.00 |
Cash Flow
CADNAVCO Pharmaceuticals Inc produced -22,361.00 in operating cash flow over the twelve months ended March 31, 2023.
| Operating Cash Flow | -22,361.00 |
| Free Cash Flow | -22,361.00 |
| FCF Per Share | -0.01 |